No Data
No Data
Buy Rating Affirmed for Legend Biotech Amid Promising Carvykti Trial Results and Expert Endorsements
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Legend Biotech (LEGN) and Intuitive Surgical (ISRG)
Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results
Genscript Biotech's (HKG:1548) subsidiary, Legend Biotech, said a phase 3 trial of Carvykti in multiple myeloma yielded "statistically significant and clinically meaningful" overall survival results,
Legend Biotech Is Maintained at Outperform by BMO Capital
Legend Biotech Is Maintained at Outperform by BMO Capital
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright analyst Mitchell Kapoor maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $73.According to TipRanks data, the analyst has a success rate of 31.7%
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
BMO Capital analyst Kostas Biliouris maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 39.3% an